The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In this November 2017 post for The JAMA Forum, Larry Levitt reviews the status of the Affordable Care Act following actions by the Trump administration widely perceived as designed to undermine the marketplaces. Despite assertions to the contrary, Levitt finds, "at least for now, the ACA seems very much alive."
In a Health Affairs blog post, Joshua M. Wiener and Melissa Romaire of RTI International and MaryBeth Musumeci of the Kaiser Family Foundation examine whether states could successfully cope with substantial reductions in federal Medicaid funding under a per capita cap or block grant system by improving efficiency in the way both acute and long-term care are delivered and paid for under the program. A review of the evidence in literature suggests that large Medicaid…
With the effort to repeal or replace the Affordable Care Act seemingly on hold or even dead, Larry Levitt discusses what the Trump administration could do to make the ACA successful - including providing clarity around individual mandate enforcement and cost-sharing reduction payments; maintaining outreach and consumer assistance; and encouraging insurers to participate in the individual insurance marketplaces. The post is now available at The JAMA Forum.
In a Health Affairs blog post, Jen Kates and Adam Wexler of the Kaiser Family Foundation and Nafis Sadat and Joseph Dieleman of the Institute for Health Metrics and Evaluation assess what cuts to U.S. global health funding as proposed in the Trump Administration FY 2018 budget request might mean in the larger context of development assistance for health.
In this May 2017 post, Karen Pollitz and co-author Kathy L. Hudson discuss how H.R. 1313, the Preserving Employee Wellness Programs Act, could substantially change current legal protections for the collection and treatment of genetic information and other personal health information under workplace wellness programs. The post is now available from the New England Journal of Medicine.
In this April 2017 post, Larry Levitt discusses the current status of the Affordable Care Act's health insurance marketplaces, and explains how the Trump administration's choices -- including whether to continue cost-sharing reduction payments to insurers -- could influence stability of the marketplaces going forward. The post is now available at The JAMA Forum.
In a Health Affairs blog post, Tricia Neuman and Gretchen Jacobson of the Kaiser Family Foundation examine how proposals to convert Medicare to a premium support system could lead to higher Medicare premiums and cost-sharing for seniors currently enrolled in the program, even if today’s seniors are “grandfathered” and the new system is phased-in for people ages 55 and younger. The blog post explains how today’s seniors could face higher health care costs, if older…
Larry Levitt's January 2017 post explains the logistics of a "repeal and delay" approach to the Affordable Care Act, and outlines key elements of a proposed replacement plan from Rep. Tom Price, who is President Trump's nominee for Secretary of Health and Human Services. The post is now available at The JAMA Forum.
Originally published in The Los Angeles Times, this perspective examines the potential implications for the individual market if key parts of the Affordable Care Act were repealed without a replacement plan.
This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.
© 2026 KFF